ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis

被引：0
|
作者：
Wei, Lai [1 ]
Wang, Qui-Qiang [2 ]
Luo, Yan [3 ]
Chu, Chi-Jen [4 ]
Paik, Seung Woon [5 ]
Hou, Jinlin [6 ]
Cheng, Jun [7 ]
Xie, Qing [8 ]
Duan, Zhongping [9 ]
Kao, Jia-Horng [10 ]
Fu, Bo [3 ]
Mobashery, Niloufar [3 ]
Heo, Jeong [11 ,12 ]
机构：
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[2] Peking Univ, Hosp 1, Beijing, Peoples R China
[3] AbbVie Inc, N Chicago, IL USA
[4] Taipei Vet Gen Hosp, Taipei, Taiwan
[5] Samsung Med Ctr, Seoul, South Korea
[6] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[7] Capital Med Univ, Beijing Di Tan Hosp, Beijing, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China
[9] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China
[10] Natl Taiwan Univ Hosp, Zhongzheng Dist, Taiwan
[11] Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea
[12] Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
875
引用
收藏
页码：434A / 434A
页数：1
相关论文
共 50 条
  • [31] Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis
    Ahmed, Hussien
    Abushouk, Abdelrahman Ibrahim
    Menshawy, Amr
    Mohamed, Arwa
    Negida, Ahmed
    Loutfy, Samah A.
    Abdel-Daim, Mohamed M.
    CLINICAL DRUG INVESTIGATION, 2017, 37 (11) : 1009 - 1023
  • [32] Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
    Antonio Ascione
    Massimo De Luca
    Mario Melazzini
    Simona Montilla
    Maria Paola Trotta
    Salvatore Petta
    Massimo Puoti
    Vincenzo Sangiovanni
    Vincenzo Messina
    Savino Bruno
    Antonio Izzi
    Erica Villa
    Alessio Aghemo
    Anna Linda Zignego
    Alessandra Orlandini
    Luca Fontanella
    Antonio Gasbarrini
    Marco Marzioni
    Edoardo G. Giannini
    Antonio Craxì
    Infection, 2018, 46 : 607 - 615
  • [33] Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
    Chen, Chun-Hsien
    Chen, Chien-Hung
    Lin, Chih-Lang
    Lin, Chun-Yen
    Hu, Tsung-Hui
    Tung, Shui-Yi
    Hsieh, Sen-Yung
    Lu, Sheng-Nan
    Chien, Rong-Nan
    Hung, Chao-Hung
    Sheen, I-Shyan
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [34] Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis
    Hussien Ahmed
    Abdelrahman Ibrahim Abushouk
    Amr Menshawy
    Arwa Mohamed
    Ahmed Negida
    Samah A. Loutfy
    Mohamed M. Abdel-Daim
    Clinical Drug Investigation, 2017, 37 : 1009 - 1023
  • [35] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders
    Sonsuz, Abdullah
    Bozcan, Selma
    Hatemi, Ibrahim
    Ozdemir, Sebati
    Canbakan, Billur
    Yildirim, Suleyman
    Gulturk, Ilkay
    Ar, Cem
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (05): : 414 - 420
  • [36] A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
    Hung, Hsuan-Yu
    Chen, Chung-Yu
    Liao, Yi-Hsiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [37] Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir
    Todt, Daniel
    Schlevogt, Bernhard
    Deterding, Katja
    Grundhoff, Adam
    Manns, Michael P.
    Wedemeyer, Heiner
    Fischer, Nicole
    Cornberg, Markus
    Steinmann, Eike
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (05) : 1541 - 1543
  • [38] Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
    Petta, Salvatore
    Marzioni, Marco
    Russo, Pierluigi
    Aghemo, Alessio
    Alberti, Alfredo
    Ascione, Antonio
    Antinori, Andrea
    Bruno, Raffaele
    Bruno, Savino
    Chirianni, Antonio
    Gaeta, Giovanni Battista
    Giannini, Edoardo G.
    Merli, Manuela
    Messina, Vincenzo
    Montilla, Simona
    Perno, Carlo Federico
    Puoti, Massimo
    Raimondo, Giovanni
    Rendina, Maria
    Silberstein, Francesca Ceccherini
    Villa, Erica
    Zignego, Anna Linda
    Pani, Luca
    Craxi, Antonio
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (06): : 427 - 434
  • [39] Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
    Liu, Chen-Hua
    Shih, Yu-Lueng
    Yang, Sheng-Shun
    Lin, Chih-Lin
    Fang, Yu-Jen
    Cheng, Pin-Nan
    Chen, Chi-Yi
    Peng, Cheng-Yuan
    Hsieh, Tsai-Yuan
    Chiu, Yen-Cheng
    Su, Tung-Hung
    Liu, Chun-Jen
    Yang, Hung-Chih
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (11) : 1977 - 1983
  • [40] Efficacy and Safety of the Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for Chronic Hepatitis C in Hemodialysis Patients
    Tosun, Guven Gurkan
    Sultanova, Fidan
    Nihan, A. K.
    Hizel, Kenan
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2019, 8
12345